Stonepine Capital, L.P. Buys 45,434 Shares of Apollo Endosurgery, Inc. (APEN) Stock

Apollo Endosurgery, Inc. (NASDAQ:APEN) major shareholder Stonepine Capital, L.P. bought 45,434 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The stock was purchased at an average price of $4.50 per share, with a total value of $204,453.00. Following the transaction, the insider now directly owns 2,410,141 shares in the company, valued at $10,845,634.50. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Stonepine Capital, L.P. also recently made the following trade(s):

  • On Friday, December 22nd, Stonepine Capital, L.P. bought 185,157 shares of Apollo Endosurgery stock. The stock was purchased at an average price of $4.85 per share, with a total value of $898,011.45.

Shares of Apollo Endosurgery, Inc. (NASDAQ:APEN) opened at $5.10 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.54 and a quick ratio of 2.00. Apollo Endosurgery, Inc. has a 12-month low of $3.55 and a 12-month high of $21.88. The firm has a market capitalization of $89.59, a P/E ratio of -0.23 and a beta of 0.46.

A number of hedge funds have recently made changes to their positions in APEN. Stonepine Capital Management LLC bought a new stake in Apollo Endosurgery in the third quarter valued at approximately $11,067,000. King Luther Capital Management Corp bought a new stake in Apollo Endosurgery in the third quarter valued at approximately $2,567,000. Russell Investments Group Ltd. bought a new stake in Apollo Endosurgery in the third quarter valued at approximately $1,288,000. Woodmont Investment Counsel LLC bought a new stake in Apollo Endosurgery in the third quarter valued at approximately $220,000. Finally, JPMorgan Chase & Co. bought a new stake in Apollo Endosurgery in the third quarter valued at approximately $119,000. Hedge funds and other institutional investors own 23.67% of the company’s stock.

Several analysts have weighed in on APEN shares. Northland Securities started coverage on Apollo Endosurgery in a research report on Tuesday, September 26th. They issued an “outperform” rating and a $12.00 price objective for the company. Zacks Investment Research upgraded Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $9.44.

ILLEGAL ACTIVITY NOTICE: This article was published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.com-unik.info/2017/12/24/stonepine-capital-l-p-buys-45434-shares-of-apollo-endosurgery-inc-apen-stock.html.

About Apollo Endosurgery

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit